Nanoparticle-mediated tumor vaccines for personalized therapy: preparing tumor antigens<i>in vivo</i>or<i>ex vivo</i>?

Human Cancer Modeling: Recapitulating Tumor Heterogeneity Towards Personalized Medicine

Despite diagnostic, preventive and therapeutic advances, growing incidence of cancer and high rate of mortality among patients affected by specific cancer types indicate current clinical measures are not ideally useful in eradicating cancer. Chemoresistance and subsequent disease relapse are believed to be mainly driven by the cell-molecular heterogeneity of human tumors that necessitates perso...

Human Cancer Modeling: Recapitulating Tumor Heterogeneity Towards Personalized Medicine

Despite diagnostic, preventive and therapeutic advances, growing incidence of cancer and high rate of mortality among patients affected by specific cancer types indicate current clinical measures are not ideally useful in eradicating cancer. Chemoresistance and subsequent disease relapse are believed to be mainly driven by the cell-molecular heterogeneity of human tumors that necessitates perso...

encapsulation of gastric tumor lysate in plga nanoparticles as antigen delivery system for anti-tumor vaccines

Sizing up circulating tumor cells for personalized therapy

Neighborhood matters: Response to EZH2 methyltransferase inhibitors Comment on: Amatangelo MD, et al. Cell Cycle 2013; 12:2113–9; PMID:23759589; http://dx.doi.org/10.4161/cc.25163 Kshipra M Gharpure and Anil K Sood*; Department of Gynecologic Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA; Center for RNA Interference and Non-Coding RNAs; The University of Texas MD ...

Targeting the tumor mutanome for personalized vaccination therapy

Next generation sequencing enables identification of immunogenic tumor mutations targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor control, qualifying mutated epitopes as source...